Surrozen (SRZN) Interest & Investment Income (2020 - 2026)
Surrozen (SRZN) posted quarterly Interest & Investment Income of $912000.0 for Q1 2026, up 208.11% year-over-year from $296000.0 in Q1 2025, and up 15.74% quarter-over-quarter from $788000.0 in Q4 2025.
Surrozen (SRZN) Interest & Investment Income (2020 - 2026) Analysis & Trends
Surrozen's Interest & Investment Income history runs 7 years deep, the most recent figure standing at $912000.0 for Q1 2026.
- In Q1 2026, Interest & Investment Income rose 208.11% year-over-year to $912000.0; the TTM figure through Mar 2026 stood at $3.6 million (up 126.68% YoY), while the FY2025 annual figure was $3.0 million, up 78.38% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $912000.0, up from $788000.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $1.0 million in Q2 2025, with the low at $49000.0 in Q1 2022.
- The 5-year median for Interest & Investment Income is $490000.0 (2024), against an average of $514470.6.
- The sharpest annual moves came in 2022 and 2024: Interest & Investment Income surged 1314.29% in 2022, then sank 34.8% in 2024.
- Surrozen's Interest & Investment Income stood at $474000.0 in 2022, then gained by 7.38% to $509000.0 in 2023, then retreated by 23.97% to $387000.0 in 2024, then jumped by 103.62% to $788000.0 in 2025, then advanced by 15.74% to $912000.0 in 2026.
- Business Quant data shows SRZN's Interest & Investment Income at $912000.0 in Q1 2026, $788000.0 in Q4 2025, and $911000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 48.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 35.58 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 27.90 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 5.13 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 28.14 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Surrozen | 281.63 Mn | 281.63 Mn | - | 938,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 938,000.00 |
| Mar 31, 2026 | 912,000.00 |
| Dec 31, 2025 | 788,000.00 |
| Sep 30, 2025 | 911,000.00 |
| Jun 30, 2025 | 1.03 Mn |
| Mar 31, 2025 | 296,000.00 |
| Dec 31, 2024 | 387,000.00 |
| Sep 30, 2024 | 431,000.00 |
| Jun 30, 2024 | 490,000.00 |
| Mar 31, 2024 | 385,000.00 |
| Dec 31, 2023 | 509,000.00 |
| Sep 30, 2023 | 661,000.00 |
| Jun 30, 2023 | 623,000.00 |
| Mar 31, 2023 | 547,000.00 |
| Dec 31, 2022 | 474,000.00 |
| Sep 30, 2022 | 198,000.00 |
| Jun 30, 2022 | 60,000.00 |
| Mar 31, 2022 | 49,000.00 |
| Dec 31, 2021 | 42,000.00 |
| Sep 30, 2021 | 14,000.00 |